Shares of Aurobindo Pharma Ltd surged 2.5% to hit a day’s high of Rs 1,250.90 on 26th February. This happened after the company said its wholly owned subsidiary, Eugia Pharma Specialities, received final approval from the US Food and Drug Administration (USFDA) for Everolimus Tablets. These are the generic version of Zortress.

Approval has been granted for Eugia Unit-I, with launch expected in the first quarter of FY27. The company can market Everolimus Tablets in four strengths. The drug is equivalent to Zortress, used to prevent organ rejection in kidney and liver transplant patients. Furthermore, the addressable market size is estimated at $78 million for the 12 months ended December 2025.

This marks Eugia’s 184th ANDA approval, including 10 tentative approvals.

For the December quarter, Aurobindo Pharma reported earnings largely ahead of estimates. Europe revenue rose 27% YoY, the ARV segment grew 22.5% YoY, and R&D spending stood at 4.7% of sales at Rs 409 crore.

At 1:06 PM, shares of Aurobindo Pharma were trading 0.92% higher at Rs 1,222.70 on the NSE.

Ready to invest like a pro? Tradz by EquityPandit equips you with 100+ Free tools and knowledge you need to succeed. Download the Tradz app and gain access to daily stock lists and insightful market analysis and much more!